Published in Antimicrob Agents Chemother on April 01, 1992
Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci U S A (1993) 6.14
Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J (1996) 3.92
High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother (1993) 3.57
Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. Antimicrob Agents Chemother (1992) 3.52
4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrob Agents Chemother (1993) 2.92
Effects of (-)-2'-deoxy-3'-thiacytidine (3TC) 5'-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha, beta, and gamma. Antimicrob Agents Chemother (1992) 2.15
Initial appearance of the 184Ile variant in lamivudine-treated patients is caused by the mutational bias of human immunodeficiency virus type 1 reverse transcriptase. J Virol (1997) 1.91
Generation of drug-resistant variants of human immunodeficiency virus type 1 by in vitro passage in increasing concentrations of 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine. Antimicrob Agents Chemother (1993) 1.86
Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-beta-L-2',3'-dideoxy-3'-thiacytidine. Antimicrob Agents Chemother (1995) 1.85
Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy. Antimicrob Agents Chemother (2008) 1.44
Limiting deoxynucleoside triphosphate concentrations emphasize the processivity defect of lamivudine-resistant variants of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother (1997) 1.28
Hepatitis B virus-induced defect of monocyte-derived dendritic cells leads to impaired T helper type 1 response in vitro: mechanisms for viral immune escape. Immunology (2003) 1.20
Antiretroviral drug resistance in human immunodeficiency virus type 2. Antimicrob Agents Chemother (2009) 1.17
Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription. Antimicrob Agents Chemother (1996) 1.16
Serum and cerebrospinal fluid pharmacokinetics of intravenous and oral lamivudine in human immunodeficiency virus-infected children. Antimicrob Agents Chemother (1998) 1.16
Human APOBEC3G-mediated editing can promote HIV-1 sequence diversification and accelerate adaptation to selective pressure. J Virol (2010) 1.15
Inhibition of human immunodeficiency virus type 1 reverse transcriptase by the 5'-triphosphate beta enantiomers of cytidine analogs. Antimicrob Agents Chemother (1994) 1.12
Specific inhibition of human immunodeficiency virus type 1 (HIV-1) integration in cell culture: putative inhibitors of HIV-1 integrase. Antimicrob Agents Chemother (2001) 1.09
Preferential incorporation of nucleoside analogs after template switching during human immunodeficiency virus reverse transcription. Antimicrob Agents Chemother (1994) 1.09
Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus. Antimicrob Agents Chemother (2001) 1.09
Use of the hepatitis B virus recombinant baculovirus-HepG2 system to study the effects of (-)-beta-2',3'-dideoxy-3'-thiacytidine on replication of hepatitis B virus and accumulation of covalently closed circular DNA. Antimicrob Agents Chemother (1999) 1.05
Generation of duck hepatitis B virus polymerase mutants through site-directed mutagenesis which demonstrate resistance to lamivudine [(--)-beta-L-2', 3'-dideoxy-3'-thiacytidine] in vitro. Antimicrob Agents Chemother (1996) 0.99
Novel 4'-substituted stavudine analog with improved anti-human immunodeficiency virus activity and decreased cytotoxicity. Antimicrob Agents Chemother (2004) 0.98
Wild-type and YMDD mutant murine leukemia virus reverse transcriptases are resistant to 2',3'-dideoxy-3'-thiacytidine. J Virol (2000) 0.97
Pharmacokinetics of (-)-2'-3'-dideoxy-3'-thiacytidine in woodchucks. Antimicrob Agents Chemother (1996) 0.97
Susceptibilities of simian immunodeficiency virus to protease inhibitors. Antimicrob Agents Chemother (2003) 0.95
A novel Met-to-Thr mutation in the YMDD motif of reverse transcriptase from feline immunodeficiency virus confers resistance to oxathiolane nucleosides. J Virol (1997) 0.95
S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1. Antimicrob Agents Chemother (1998) 0.95
Efficacy of antiretroviral agents against murine replication-competent retrovirus infection in human cells. J Virol (1999) 0.94
In vitro immunotoxicity of +/- 2'-deoxy-3'-thiacytidine, a new anti-HIV agent. Clin Exp Immunol (1993) 0.93
Gag-Pol supplied in trans is efficiently packaged and supports viral function in human immunodeficiency virus type 1. J Virol (2001) 0.93
Nelfinavir and Lamivudine pharmacokinetics during the first two weeks of life. Pediatr Infect Dis J (2011) 0.92
Backs against the wall: novel and existing strategies used during the 2014-2015 Ebola virus outbreak. Clin Microbiol Rev (2015) 0.92
3'-Azido-3'-deoxythymidine (AZT) mediates cross-resistance to nucleoside analogs in the case of AZT-resistant human immunodeficiency virus type 1 variants. J Virol (1998) 0.92
Effect of lamivudine on transmission of human T-cell lymphotropic virus type 1 to adult peripheral blood mononuclear cells in vitro. Antimicrob Agents Chemother (2002) 0.92
Intracellular metabolism and persistence of the anti-human immunodeficiency virus activity of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel thymidine analog. Antimicrob Agents Chemother (2007) 0.91
Comparative evaluation of virus transmission inhibition by dual-acting pyrimidinedione microbicides using the microbicide transmission and sterilization assay. Antimicrob Agents Chemother (2008) 0.90
Antiretroviral agents inhibit infection of human cells by porcine endogenous retroviruses. Antimicrob Agents Chemother (2000) 0.86
Impact of maternal and infant antiretroviral drug regimens on drug resistance in HIV-infected breastfeeding infants. Pediatr Infect Dis J (2013) 0.84
Antiviral activities of MCC-478, a novel and specific inhibitor of hepatitis B virus. Antimicrob Agents Chemother (2002) 0.84
Increased activation of the combination of 3'-azido-3'-deoxythymidine and 2'-deoxy-3'-thiacytidine in the presence of hydroxyurea. Antimicrob Agents Chemother (1997) 0.83
Cytotoxicological analysis of a gp120 binding aptamer with cross-clade human immunodeficiency virus type 1 entry inhibition properties: comparison to conventional antiretrovirals. Antimicrob Agents Chemother (2009) 0.82
Modulation of the metabolism of beta-L-(-)-2',3'-dideoxy-3'-thiacytidine by thymidine, fludarabine, and nitrobenzylthioinosine. Antimicrob Agents Chemother (1997) 0.80
Is infant exposure to antiretroviral drugs during breastfeeding quantitatively important? A systematic review and meta-analysis of pharmacokinetic studies. J Antimicrob Chemother (2015) 0.78
Clinical pharmacokinetics of alamifovir and its metabolites. Antimicrob Agents Chemother (2005) 0.77
Mutations outside the YMDD motif in the P protein can also cause DHBV resistant to Lamivudine. World J Gastroenterol (2005) 0.75
HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science (1989) 14.63
3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci U S A (1985) 10.71
Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science (1991) 8.76
The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med (1987) 8.52
Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci U S A (1986) 8.48
Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J Virol Methods (1988) 7.74
Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides. Proc Natl Acad Sci U S A (1986) 6.63
Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet (1986) 5.05
Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lancet (1988) 3.37
The separated enantiomers of 2'-deoxy-3'-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro. Antimicrob Agents Chemother (1992) 3.22
In vivo activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosine. Science (1989) 2.70
2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial. N Engl J Med (1990) 2.52
Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2'-deoxy-3'-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog. Antimicrob Agents Chemother (1991) 2.40
Resumption of virus production after human immunodeficiency virus infection of T lymphocytes in the presence of azidothymidine. J Virol (1987) 2.33
Ribavirin antagonizes inhibitory effects of pyrimidine 2',3'-dideoxynucleosides but enhances inhibitory effects of purine 2',3'-dideoxynucleosides on replication of human immunodeficiency virus in vitro. Antimicrob Agents Chemother (1987) 2.24
Once-daily administration of 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. Results of a Phase I trial. N Engl J Med (1990) 1.81
Nature, time course and dose dependence of zidovudine-related side effects: results from the Multicenter Canadian Azidothymidine Trial. AIDS (1989) 1.78
AZT (zidovudine) may act postintegrationally to inhibit generation of HIV-1 progeny virus in chronically infected cells. Virology (1990) 1.64
Anti-human immunodeficiency virus synergism by zidovudine (3'-azidothymidine) and didanosine (dideoxyinosine) contrasts with their additive inhibition of normal human marrow progenitor cells. Antimicrob Agents Chemother (1991) 1.45
Azidothymidine associated with bone marrow failure in the acquired immunodeficiency syndrome (AIDS). Ann Intern Med (1987) 1.27
Anti-HIV compound assessment by two novel high capacity assays. J Virol Methods (1989) 1.20
Anemia and erythropoiesis in patients with the acquired immunodeficiency syndrome (AIDS) and Kaposi sarcoma treated with zidovudine. Ann Intern Med (1988) 1.19
New acquisitions in the development of anti-HIV agents. Antiviral Res (1989) 1.18
Initial clinical experience with dideoxynucleosides as single agents and in combination therapy. Ann N Y Acad Sci (1990) 1.12
3'-Azido-3'-deoxythymidine inhibits the replication of avian leukosis virus. J Virol (1987) 0.98
High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother (1993) 3.57
The separated enantiomers of 2'-deoxy-3'-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro. Antimicrob Agents Chemother (1992) 3.22
Construction and characterization of a herpes simplex virus type 1 mutant unable to transinduce immediate-early gene expression. J Virol (1989) 3.19
The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine. Antimicrob Agents Chemother (1993) 3.00
4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrob Agents Chemother (1993) 2.92
Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en. J Virol (1996) 2.26
Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase). Antimicrob Agents Chemother (1994) 2.22
Effects of (-)-2'-deoxy-3'-thiacytidine (3TC) 5'-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha, beta, and gamma. Antimicrob Agents Chemother (1992) 2.15
Translation deficiency of the Sabin type 3 poliovirus genome: association with an attenuating mutation C472----U. Virology (1990) 2.03
Generation and characterization of variants of NWS/G70C influenza virus after in vitro passage in 4-amino-Neu5Ac2en and 4-guanidino-Neu5Ac2en. Antimicrob Agents Chemother (1996) 1.94
Association of brain damage with therapeutic abortion induced by amniotic-fluid replacement: report of two cases. Br Med J (1966) 1.83
Single mutations at many sites within the DNA polymerase locus of herpes simplex viruses can confer hypersensitivity to aphidicolin and resistance to phosphonoacetic acid. J Gen Virol (1984) 1.66
The indirect costs of graduate medical education. N Engl J Med (1985) 1.65
Development of HIV-1 resistance to (-)2'-deoxy-3'-thiacytidine in patients with AIDS or advanced AIDS-related complex. AIDS (1995) 1.58
Cellular metabolism of (-) enantiomeric 2'-deoxy-3'-thiacytidine. Biochem Pharmacol (1992) 1.57
The battered child syndrome. Med Sci Law (1966) 1.56
Neutralizing (54K) and non-neutralizing (54K and 48K) monoclonal antibodies against structural and non-structural yellow fever virus proteins confer immunity in mice. J Gen Virol (1986) 1.55
Sudden death in infancy in Inner North London. J Pathol (1975) 1.53
Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro. J Virol (2005) 1.53
Examination of the immunological relationships between flaviviruses using yellow fever virus monoclonal antibodies. J Gen Virol (1985) 1.50
Nucleotide sequence of a neurovirulent variant of the type 2 oral poliovirus vaccine. J Virol (1989) 1.46
Evidence for the involvement of influenza A (fowl plague Rostock) virus protein P2 in ApG and mRNA primed in vitro RNA synthesis. J Gen Virol (1981) 1.35
Inhibition of replication of avian influenza viruses by the neuraminidase inhibitor 4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid. Virology (1995) 1.24
Case-mix and resource use in long-term care. Med Care (1985) 1.22
Virus excretion and mutation by infants following primary vaccination with live oral poliovaccine from two sources. J Med Virol (1990) 1.22
Inhibition of the growth of influenza viruses in vitro by 4-guanidino-2,4-dideoxy-N-acetylneuraminic acid. Antiviral Res (1994) 1.17
HIV protease genotype and viral sensitivity to HIV protease inhibitors following saquinavir therapy. AIDS (1998) 1.13
Capped mRNAs may stimulate the influenza virion polymerase by allosteric modulation. Virus Res (1984) 1.13
Comparison of the immediate early polypeptides of human cytomegalovirus isolates. J Gen Virol (1981) 1.12
Advances in toxicology. Practitioner (1971) 1.11
The intracellular phosphorylation of (-)-2'-deoxy-3'-thiacytidine (3TC) and the incorporation of 3TC 5'-monophosphate into DNA by HIV-1 reverse transcriptase and human DNA polymerase gamma. Biochem Pharmacol (1995) 1.11
Characterization of envelope glycoprotein gp41 genotype and phenotypic susceptibility to enfuvirtide at baseline and on treatment in the phase III clinical trials TORO-1 and TORO-2. AIDS Res Hum Retroviruses (2006) 1.10
The human amnion is a site of MHC class Ib expression: evidence for the expression of HLA-E and HLA-G. J Immunol (1995) 1.05
Fatal subarachnoid haemorrhage associated with cervical trauma. Med Sci Law (1972) 1.01
Anti-human immunodeficiency virus and anti-hepatitis-B virus activities and toxicities of the enantiomers of 2'-deoxy-3'-oxa-4'-thiocytidine and their 5-fluoro analogues in vitro. J Med Chem (1995) 1.01
Use of the biotin-streptavidin interaction to improve flavivirus detection by immunofluorescence and ELISA tests. J Virol Methods (1985) 0.99
A consensus sequence for substrate hydrolysis by rhinovirus 3C proteinase. FEBS Lett (1989) 0.96
Sequencing and functional expression of the malonyl-CoA-sensitive carnitine palmitoyltransferase from Drosophila melanogaster. Biochem J (1999) 0.96
DNA chain termination activity and inhibition of human immunodeficiency virus reverse transcriptase by carbocyclic 2',3'-didehydro-2',3'-dideoxyguanosine triphosphate. J Biol Chem (1992) 0.95
The synthesis and antiviral activity of 4-fluoro-1-beta-D-ribofuranosyl-1H-pyrazole-3-carboxamide. Nucleosides Nucleotides (1999) 0.93
Evolution of genotypic and phenotypic resistance during chronic treatment with the fusion inhibitor T-1249. AIDS Res Hum Retroviruses (2007) 0.93
The state and future of Mars polar science and exploration. Icarus (2000) 0.91
Hydrolysis of a series of synthetic peptide substrates by the human rhinovirus 14 3C proteinase, cloned and expressed in Escherichia coli. J Gen Virol (1989) 0.90
Immediate postoperative death associated with severe laryngeal obstruction. Med Sci Law (1972) 0.89
A novel mitochondrial DNA mutation in COX1 leads to strokes, seizures, and lactic acidosis. Neuropediatrics (2009) 0.89
Topographical analysis of epitope relationships on the envelope glycoprotein of yellow fever 17D vaccine and the wild type Asibi parent virus. Virology (1986) 0.88
Nuclear transfer studies of Amoeba proteus after the inhibition of cell division by injection of non-homologous cytoplasm. Biochem Biophys Res Commun (1973) 0.88
The battered baby syndrome. Practitioner (1972) 0.87
Single dose and fractionated palliative irradiation for osseous metastases. Clin Radiol (1976) 0.86
The critical cut-off temperature of avian influenza viruses. Virus Res (1990) 0.86
4-Guanidino-Neu5Ac2en fails to protect chickens from infection with highly pathogenic avian influenza virus. Antiviral Res (1995) 0.85
Immune reconstitution in HAART-treated children with AIDS. Highly Active Anti-Retroviral Therapy. Lancet (1998) 0.85
Traumatic "myocarditis" or "myocarditis" in trauma. Med Sci Law (1968) 0.84
The kinetics of the acid-induced conformational change of influenza virus haemagglutinin can be followed using 1,1'-bis(4-anilino-5-naphthalenesulphonic acid). Biochem Biophys Res Commun (1995) 0.84
Pyruvate dehydrogenase phosphatase deficiency: orphan disease or an under-diagnosed condition? Mol Cell Endocrinol (2006) 0.84
Use of six chimeric proteins to investigate the role of intramolecular interactions in determining the kinetics of carnitine palmitoyltransferase I isoforms. J Biol Chem (2000) 0.84
The low potential for drug interactions with zanamivir. Clin Pharmacokinet (1999) 0.84
Extragenic suppression of a ts phenotype during recombination between ts mutants of two fowl plague virus strains with a ts mutation in gene 1. J Gen Virol (1982) 0.84
Increased sensitivity of virus-infected cells to inhibitors of protein synthesis does not correlate with changes in plasma membrane permeability. Virology (1986) 0.84
Selection in vitro of an HIV-1 variant resistant to both lamivudine (3TC) and zidovudine. AIDS (1996) 0.82
TTY2: a multicopy Y-linked gene family. Genome Res (2001) 0.82
Degeneracy in human multicopy RBM (YRRM), a candidate spermatogenesis gene. Mamm Genome (1996) 0.82
Conditions for haemolysis by flaviviruses and characterization of the haemolysin. J Gen Virol (1985) 0.82
Carbovir: the (-) enantiomer is a potent and selective antiviral agent against human immunodeficiency virus in vitro. Antiviral Res (1991) 0.82
Use of a monoclonal antibody specific for wild-type yellow fever virus to identify a wild-type antigenic variant in 17D vaccine pools. J Gen Virol (1989) 0.82
Brain damage following therapeutic abortion by amniotic fluid replacement: an experimental approach. J Obstet Gynaecol Br Commonw (1969) 0.82
Plasmodium falciparum lacks sialidase and trans-sialidase activity. Parasitology (1996) 0.80
Scanning electron microscopy: application in the identification of diatoms in cases of drowning. J Forensic Sci (1992) 0.79
Bite-marks in the 'battered baby syndrome'. Med Sci Law (1973) 0.79
Susceptibility in cell culture of feline immunodeficiency virus to eighteen antiviral agents. J Antimicrob Chemother (1994) 0.79
Identification of the cap-binding protein of two strains of influenza A/FPV. J Gen Virol (1982) 0.79
Recent development in the design of antiviral agents. Med Res Rev (1995) 0.79
In vitro resistance development for RO-0335, a novel diphenylether nonnucleoside reverse transcriptase inhibitor. Antiviral Res (2010) 0.78
Synthesis and structure-activity relationships of a series of penicillin-derived HIV proteinase inhibitors: heterocyclic ring systems containing P1' and P2' substituents. J Med Chem (1994) 0.78
Molecular biology and the control of viral vaccines. FEMS Microbiol Immunol (1990) 0.78
A theoretical analysis of the dynamics of oxygen transport and exchange in the placental-fetal system. Microvasc Res (1974) 0.78
Diffuse axonal injury in early infancy. J Clin Pathol (1987) 0.78
Resistance to (-)-2',3'-dideoxy-3'-thiacytidine (3TC) in HIV-1 isolated from paediatric patients. Antivir Ther (1996) 0.77
Benzophenone derivatives: a novel series of potent and selective inhibitors of human immunodeficiency virus type 1 reverse transcriptase. J Med Chem (1995) 0.77
A series of penicillin derived C2-symmetric inhibitors of HIV-1 proteinase: synthesis, mode of interaction, and structure-activity relationships. J Med Chem (1993) 0.77
The diagnosis of drowning by quantitative and qualitative diatom analysis. Med Sci Law (1993) 0.76
Measuring the effectiveness of antiretroviral agents. Antivir Ther (2001) 0.76
The demographic responses to famine: the case of China 1958-61. GeoJournal (1991) 0.76
Ideology and policy termination: restructuring California's mental health system. Public Policy (1978) 0.76
Novel polypeptides encoded by influenza virus subgenomic (DI type) virion RNAs. Virus Res (1985) 0.76